UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by investment analysts at Cowen in a research note issued to investors on Tuesday.

Other research analysts have also issued research reports about the company. Oppenheimer restated a “buy” rating and issued a $75.00 target price (up previously from $62.00) on shares of UroGen Pharma in a report on Tuesday, April 3rd. Jefferies Group restated a “buy” rating on shares of UroGen Pharma in a report on Monday, March 19th. Ladenburg Thalmann restated a “buy” rating and issued a $65.00 target price on shares of UroGen Pharma in a report on Friday, March 16th. Zacks Investment Research upgraded UroGen Pharma from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine upgraded UroGen Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $45.50.

Shares of UroGen Pharma opened at $62.75 on Tuesday, MarketBeat reports. UroGen Pharma has a 52-week low of $61.05 and a 52-week high of $61.50. The company has a market capitalization of $847.91 million and a price-to-earnings ratio of -29.04.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, May 15th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.15). The firm had revenue of $0.48 million during the quarter. equities analysts expect that UroGen Pharma will post -3.21 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of UroGen Pharma during the fourth quarter valued at approximately $166,000. JPMorgan Chase & Co. purchased a new stake in shares of UroGen Pharma during the third quarter valued at approximately $168,000. Quantbot Technologies LP purchased a new stake in shares of UroGen Pharma during the first quarter valued at approximately $174,000. UBS Group AG increased its position in shares of UroGen Pharma by 31.5% during the first quarter. UBS Group AG now owns 3,611 shares of the company’s stock valued at $180,000 after acquiring an additional 865 shares during the last quarter. Finally, MYDA Advisors LLC purchased a new stake in shares of UroGen Pharma during the fourth quarter valued at approximately $223,000. Institutional investors own 53.00% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Analyst Recommendations for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.